Haleon plc Buys Back Own Shares
Ticker: HLNCF · Form: 6-K · Filed: Sep 25, 2024 · CIK: 1900304
Sentiment: neutral
Topics: share-buyback, transaction
TL;DR
Haleon bought back its own stock on 9/25. Details light, but usually a good sign.
AI Summary
Haleon plc announced on September 25, 2024, that it conducted a transaction in its own shares. The filing does not specify the number of shares or the total value of the transaction, but it indicates a buyback or similar activity by the company.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of a share transaction by the company, with no immediate negative or positive financial implications stated.
Key Players & Entities
- Haleon plc (company) — Registrant
- 25 September 2024 (date) — Transaction Date
- 001-41411 (other) — Commission File Number
FAQ
What specific number of Haleon plc shares were transacted on September 25, 2024?
The filing does not specify the exact number of shares involved in the transaction.
What was the total monetary value of the transaction in Haleon plc's own shares?
The filing does not disclose the total monetary value of the transaction.
What is the purpose of this 'Transaction in Own Shares' filing?
This filing is a report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, detailing a transaction in the company's own shares.
Is Haleon plc filing an annual report on Form 20-F or 40-F?
Haleon plc indicates it files annual reports under cover of Form 20-F.
What was Haleon plc's former name?
Haleon plc's former name was DRVW 2022 Ltd.
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-09-25 13:31:24
Filing Documents
- a6882f.htm (6-K) — 28KB
- 0001654954-24-012283.txt ( ) — 30KB
From the Filing
IN OWN SHARES a6882f   UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2024   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1  25 September 2024 - Transaction in Own Shares         99.1     Haleon plc: Transaction in own shares   25 September 2024: Haleon plc (the “Company” or “Haleon”) today announces the purchase of the following number of ordinary shares of £0.01 each in the Company (the “Shares”) for cancellation under its share buyback programme announced on 1 August 2024 (the “Buyback Programme”).   Date of purchase: 25 September 2024 Number of Shares purchased: 510,000 Highest price paid per Share (p): 395.6000 Lowest price paid per Share (p): 391.2000 Volume weighted average price paid per Share (p): 393.4714   Following the settlement of the above, the Company's registered share capital consists of 9,114,395,197 ordinary shares. This figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5s(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/6877F_1-2024-9-25.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors .   Enquiries     Investors Media Sonya Ghobrial +44 7392 784784 Zoë Bird +44 7736 746167 Rakesh Patel +44 7552 484646 Gemma Thomas +44 7985 175048 Emma White +44 7823 523562     Email: investor-relations@haleon.com Email: corporate.media@haleon.com   About Haleon Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .                    SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 25, 2024 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary